comprehensive -WSS

comprehensive

author：leisure time 2025-09-01 15:16:17 - browse：4

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： As AI in medicine takes off, can 'human in the loop' prevent harm?

WSS

RaDonda Vaught links Vanderbilt hospital issues to patient death

Surge in Apellis stock fueled by confidence in safety of its eye drug

Senators push IRS to launch nonprofit hospital probe

Biogen’s boardroom scandal saddles CEO with first crisis

Ebola: Gilead Sciences antiviral shows promise as new treatment

Biden administration begins canceling student loan debt for 804,000 borrowers

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

Bayer exec: U.S. is key in reviving beleaguered pharma’s drug pipeline

Hollywood unions extend contract negotiations for actors

Idaho college killings prosecutors challenge defense's grand jury claims

At least 13 dead in Texas as scorching temps continue

Health AI: on the border between health care and tech

Drug repurposing or repositioning? The language matters

WuXi out of biotech trade group, U.S. and China relations to blame

Duchenne breakthrough therapy leaves behind pioneering families

Illumina slashes 2023 revenue projections yet again

hotspot

FDA advisers back CAR

Montana youths win climate lawsuit against state for promoting fossil fuels

HHS secretary Becerra pressed on Change HealthCare cyberattack

UCLA team creates talking throat patch for voice disorders

Readout Newsletter: Bristol, Sangamo, Gilead, and more

YouTube cracks down on misinformation on cancer treatment

knowledge

leisure time

leisure time

focus